Opioid Withdrawal Clinical Trial: Dr. Andy Chambers Announces New Study with Tezampanel

Dr. Andy Chambers of Aspire Indiana Health announces a new clinical trial to test the effects of tezampanel (TZP) in reducing opioid withdrawal symptoms and helping patients with opioid use disorder (OUD) transition to full remission with injectable naltrexone. Learn more about this promising research!

#OpioidWithdrawal #ClinicalTrial #Tezampanel #OUD #AddictionRecovery #Naltrexone #OpioidCrisis #AspireIndiana

Leave a comment

Your email address will not be published. Required fields are marked *